Tag: Data

Categories
Health

Israeli information counsel mass vaccinations led to drop in extreme Covid instances, CDC examine finds

Israeli data suggest mass vaccinations led to drop in severe Covid cases, CDC study finds

An Israeli health worker from Maccabi Healthcare Services prepares to administer a dose of the Pfizer BioNtech vaccine in Tel Aviv on February 24, 2021.

Jack Guez | AFP | Getty Images

Data from Israel, which vaccinated the vast majority of its elderly population with the Pfizer Covid-19 vaccine, suggests that mass vaccination has prevented people from getting seriously ill, according to a new study by the Centers for Disease Control and Prevention.

While clinical studies have shown the Pfizer BioNTech vaccine to be 95% effective at preventing Covid-19, the Israeli data provide early insight into the vaccine’s effectiveness in an uncontrolled, real-world setting.

The study, published Friday in the CDC’s weekly report on morbidity and mortality, found that among the most vaccinated portion of the Israeli population, the percentage of patients requiring ventilation has dropped dramatically, suggesting a reduction in the serious illness.

“Taken together, these results suggest a reduced rate of severe COVID-19 after vaccination,” wrote researchers from Ben Gurion University in the Negev, Tel Aviv University and Maccabi Healthcare Services.

Israel launched its national vaccination campaign in December, prioritizing people aged 60 and over, healthcare workers and people with comorbid illnesses. By February, according to the researchers, 84% of the population aged 70 and over had been fully immunized with the Pfizer-BioNTech two-shot vaccine. Only 10% of the population under the age of 50 had been vaccinated at any one time, the researchers said.

The researchers compared the number of Covid-19 patients aged 70 and over who needed a mechanical ventilator with those under 50 who needed a ventilator. The researchers said they needed a ventilator, a medical tool that helps patients breathe, to measure severe Covid-19.

Between October and February, the number of patients aged 70 and over who needed a ventilator decreased. At the same time, the number of people under the age of 50, a generally unvaccinated population, who needed a ventilator, the study found. The country began using gunshots on mostly elderly people on December 20. A second round of shooting followed three weeks later.

The researchers noted some limitations to the study. Israel put in place a strict national stay-at-home order on Jan. 8, weeks after the vaccination campaign began, which could have resulted in a decline in seriously ill patients who would have needed ventilators. The introduction of new variants of the coronavirus could also have affected the data.

The researchers said their results are preliminary, “important evidence of the effectiveness of vaccines in preventing severe cases of COVID-19 at the national level in Israel”.

“Getting COVID-19 vaccines to eligible individuals can help limit the spread of disease and potentially reduce the incidence of serious diseases,” they write.

Categories
Health

N.Y.C. Covid Vaccine Disparities Revealed in ZIP Code Knowledge: Officers

N.Y.C. Covid Vaccine Disparities Revealed in ZIP Code Data: Officials

“The zip code data not only provides a map of where New Yorkers will be vaccinated, but also a roadmap for our Covid response,” said Dr. Easterling.

Also on Tuesday, Governor Andrew M. Cuomo released data showing that white people were vaccinated more frequently than expected in every region across the state. But in most regions, blacks were vaccinated at about half the expected rate.

In New York City, for example, 58 percent of those vaccinated were white, while white people made up just 52 percent of the eligible population, according to the state. About 14.4 percent of those vaccinated were black, although more than 30 percent of the eligible population were black.

About 16 percent of people vaccinated in the city were Hispanic or Latino, but Hispanic or Latino make up about 24 percent of the eligible population, according to the state.

Experts say people across the country who live in underserved areas face a variety of barriers to vaccination, including registration systems and websites that can take hours to navigate, lack of transportation, and difficulty getting off work to get one Chance to get. Given the history of unethical medical research in the United States, many people in color communities are more reluctant to get vaccinated.

Mr de Blasio said Tuesday that a new vaccination site opened on Wednesday at Teachers Preparatory High School in Brownsville, Brooklyn, open six days a week, giving priority to home health workers and those living in Brownsville and East New York.

“This is about addressing inequality and doing something very tangible about it,” he said.

Another new vaccination site will open at the Empire Outlets in Staten Island on Thursday, he said.

The city vaccinated 317,227 people last week, including 55,339 people in one day, de Blasio said, adding that more than 10 percent of New Yorkers would now have received at least one dose. He said the city could vaccinate far more people each day if it could get more doses from the federal government.

Categories
World News

Japan’s preliminary GDP knowledge forward; China, Hong Kong closed

Japan's preliminary GDP data ahead; China, Hong Kong closed

SINGAPORE – Stocks in Japan should rise on Monday as several markets in North Asia closed for the New Year holidays.

Futures indicated a higher open for Japanese stocks. The Nikkei futures contract in Chicago was at 29,725 while its Osaka counterpart was at 29,590. This is compared to the Nikkei 225’s last closing price at 29,520.07.

Japan’s preliminary pressure on fourth quarter gross domestic product is expected around 7:50 a.m. HK / SIN.

Australian stocks rose in morning trade, with the S & P / ASX 200 up around 0.8%.

The markets in China, Hong Kong, Taiwan and the USA are closed on Mondays for public holidays.

Currencies

The US dollar index, which tracks the greenback against a basket of its peers, stood at 90.422 after weakening against the 91.2 handle earlier this month.

The Japanese yen was trading at 104.98 per dollar, weaker than below 104.8 against the greenback last week. The Australian dollar was trading at $ 0.7766 after rising below $ 0.772 last week.

Here’s a look at what’s on tap:

  • Japan: Preliminary gross domestic product data for the fourth quarter at 7:50 a.m. HK / SIN
Categories
Health

Biden Pushes for Racial Fairness in Vaccination, however Information Lags

Biden Pushes for Racial Equity in Vaccination, but Data Lags

“Soon after we started this vaccination, I started asking for this data – I wanted it, we needed it, we tried to get it, and we found problems,” said Dr. Romero, who is also the chairman of the CDC Advisory Committee on Immunization Practices, said in an interview. He said several state epidemiologists were at work “to fill in the gaps by cross-referencing secondary sources.”

Updated

Apr. 9, 2021 at 10:21 AM ET

Just as the pandemic exposed racial differences in healthcare, it exposed differences in vaccination. Blacks and Latinos are far more likely to become infected than whites and die from Covid-19. And in cities across the country, including here in Washington, wealthy white residents line up to get vaccinated in low-income Latin American and black communities.

People in underserved neighborhoods face a variety of obstacles, experts say, including registration phone lines and websites that can take hours to navigate, and lack of transportation or a break from work to get to appointments. And people of color, especially blacks, are more reluctant to get vaccinated, given the history of unethical medical research in the United States.

The community health center program aims to fill this gap. It will be relatively small at first; The government is distributing a million doses to just 250 of the country’s so-called state-qualified health centers. There are nearly 1,400 centers operating 13,000 sites serving nearly 30 million patients – about one in 11 Americans, according to the Health Resources and Services Administration, which funds the program.

Overall, the rate of vaccination is increasing given the slow growth in supply, which remains a limiting factor. As of Tuesday, the CDC average of vaccine doses administered in the United States over seven days was approximately 1.49 million doses per day.

When Mr. Biden became president, the federal government was shipping 8.6 million doses of vaccine to states each week. That number is set to climb to 11 million – a 28 percent increase, Jeffrey D. Zients, Mr Biden’s coronavirus response coordinator, told reporters Tuesday. This corresponds to the expected increases in production.

The one million doses to the community clinics are provided in addition to supplies to the states. Separately, the White House announced last week that administration would begin shipping an additional million doses to 6,500 pharmacies on Thursday.

Categories
Health

Birx says somebody was giving Trump ‘parallel knowledge’ about Covid pandemic

Birx says someone was giving Trump 'parallel data' about Covid pandemic

Deborah Birx, Coronavirus Response Coordinator for the White House Coronavirus Task Force, speaks after a White House Coronavirus Task Force briefing at the Department of Health and Human Services in Washington, DC on June 26, 2020.

Joshua Roberts | Getty Images

Dr. Deborah Birx, Trump’s White House coronavirus response coordinator, said in a CBS interview published Sunday that former President Donald Trump was reviewing “parallel” coronavirus pandemic records from someone within the administration.

“I’ve seen the President show off graphics that I’ve never done,” Birx told Margaret Brennan on CBS News’ Face The Nation. “Someone inside created a parallel set of data and graphs that were shown to the President.”

Birx, who announced her resignation as President Joe Biden last week, said she did not know the identity of the person who gave other information to the president. She added that there were Covid-19 deniers within the Trump administration.

“There were people who definitely thought this was a joke,” she said. “I think the information was confusing at first. I think because we weren’t talking about the spectrum of the disease, everyone interpreted what they knew.”

According to the Johns Hopkins University, more than 25 million people have been infected and at least 417,000 people have died in the United States since the pandemic began.

Birx said she had always considered resigning from the White House’s coronavirus task force and was censored by the Trump administration, but denied ever withholding information about the virus.

“When you have a pandemic where you rely on every American to change their behavior, communication is absolutely vital,” she said. “Every time a political leader made a statement that didn’t meet public health needs, our response got derailed. That’s why I took to the streets because I wasn’t censored along the way.”

Birx also said she was increasingly concerned about the Trump administration’s pandemic strategy, particularly right before the presidential election. At the start of the pandemic, Birx had approved of the government’s response, but later frustrated Trump when she emphasized the severity of the pandemic.

“My colleagues, whom I had known for decades – decades – in that one experience because I was in the White House, decided that I had become that political person even though they had known me forever,” said Birx. “I had to ask myself every morning, ‘Is there something I think I can do to respond to this pandemic?’ And that’s what I asked myself every evening. “

Categories
Business

Knowledge Recorder Recovered From Indonesian Aircraft Crash

Data Recorder Recovered From Indonesian Plane Crash

Divers of the Indonesian Navy have recovered the flight data recorder from Sriwijaya Air Flight 182, which crashed into the Java Sea shortly after take-off on Saturday with 62 people on board.

The remains of some victims were also brought ashore in dozens of body bags, officials said. So far, four victims have been identified. No survivors of the flight are expected.

The quick recovery of the flight data recorder, sometimes referred to as a “black box” and one of two on the plane, helps officials understand why the 26-year-old Boeing 737-500 was just four minutes after take off from Jakarta, the capital. The plane flew to Pontianak on the island of Borneo, a flight of about 90 minutes.

The divers retrieved the flight data recorder from the wreck in about 75 feet of water between the islets of Lancang and Laki, officials said.

The Boeing had two data recorders on opposite ends of the aircraft: a flight data recorder in the rear of the aircraft, which can provide information about the mechanical operation of the jet during its short flight; and a cockpit voice recorder that records the conversation between the pilot and the copilot.

Investigators hope that analyzing the information found on both devices can provide a clear picture of what happened during the flight.

The plane crashed nearly 300 meters shortly after taking off from Soekarno-Hatta International Airport in Jakarta. The wreck extends over an area of ​​about 300 meters in length and 300 meters in width, the authorities said.

The relatively compact size of the debris field is consistent with an airplane that did not explode before hitting the water.

Each data recorder has an acoustic underwater beacon that emits a signal in the event of a crash to help those searching for the recorder to recover.

But in this case, the acoustic beacon broke away from the cockpit voice recorder and was found separately, said Indonesian Armed Forces commander Hadi Tjahjanto.

Divers continue to search for the recorder itself, he told reporters.

“We are sure that the cockpit voice recorder will also be found,” he said.

Sriwijaya Air released a statement that the aircraft had received a certificate of airworthiness from the Ministry of Transport that was valid until December 17, 2021.

A ministry spokeswoman Adita Irawati said the aircraft’s certificate of operation was renewed in November.

“Sriwijaya Air met the conditions set,” she said.

The latest crash adds to a list of previous airline tragedies in Indonesia. Air Asia Flight 8501 crashed into the Java Sea off the coast of Borneo in December 2014. In October 2018, Lion Air Flight 610 plunged into the Java Sea northeast of Jakarta a few minutes after take-off.

Dera Menra Sijabat reported from Jakarta, Indonesia.

Categories
Health

Turkey and Brazil Say Chinese language Vaccine Efficient, With Sparse Supporting Knowledge

Turkey and Brazil Say Chinese Vaccine Effective, With Sparse Supporting Data

Turkish officials announced Thursday that a vaccine made by Chinese company Sinovac has an efficacy rate of 91.25 percent. However, the finding is based on preliminary results from a small clinical study, and none of the data has been published in a journal or published online.

The announcement came a day after another ambiguous press conference, also on Sinovac’s vaccine, in Brazil. Officials there were expected to provide detailed results from another study, but they only reported that the vaccine had an efficacy rate of over 50 percent.

A total of 7,371 volunteers were involved in the Turkish study, but efficacy data from Infectious Disease Expert Serhat Unal was based on just 1,322 participants, of whom 752 received a real vaccine and 570 received the placebo.

Dr. Unal said that 26 of the volunteers who received the placebo developed Covid-19 while only three of the vaccinated volunteers became ill. He and his colleagues did not pass on their data in writing.

“Now we are sure that the vaccine is effective and safe for the Turks,” said Fahrettin Koca, the health minister.

Sinovac did not make a public statement about the trial, nor did he comment on the trial in Brazil.

Updated

Apr. 25, 2020, 4:08 pm ET

The small number of volunteers that the Turkish researchers relied on to calculate effectiveness raised questions about the safety of their conclusions. The more people take part in a vaccine clinical study, the more statistical it is.

In contrast, Pfizer and BioNTech provided data on 36,523 people to show that the vaccine had a 95 percent effectiveness rate. For their vaccine, 162 people who received the placebo developed Covid, compared to eight people in the group who received the vaccine.

Turkey has signed a contract with Sinovac for 50 million doses of the vaccine. The first three million cans are due to arrive in Turkey on Monday, Koca said. Mr Koca said Turkey will also receive 4.5 million doses of the Pfizer BioNTech vaccine by the end of March. Around 1 million cans are expected to arrive by the end of January, he said.

CoronaVac, as Sinovac calls its vaccine, is made from killed coronaviruses. The method is one of the oldest for making vaccines that Jonas Salk used to make a vaccine against polio in the 1950s. After viruses are inactivated with chemicals, they cannot make people sick, but they can stimulate the immune system to make antibodies that can provide long-term protection against live viruses.

Sinovac developed CoronaVac in early 2020 and then conducted a number of clinical studies. They published their results in November. There they reported that the vaccine appeared safe and produced an immune response against the coronavirus.

The company then moved on to phase 3 trials in Brazil, Indonesia and Turkey, three countries with high rates of Covid-19.

Health officials in Brazil said Wednesday that the Chinese vaccine had passed safety and effectiveness tests that would pave the way for its use in Brazil. However, they postponed the publication of detailed data from clinical trials in Brazil on which these results are based, citing a contractual agreement with Sinovac. Dimas Covas, the director of the butantane institute that conducted the trials, said a joint announcement could be made within two weeks.

“Today is a historic day for science and for Brazilian health,” Jean Gorinchteyn, Sao Paulo State Minister of Health, told reporters at a press conference. “This will allow us to save the lives of millions of people, not just in Brazil, but around the world.”

Categories
Business

Treasury yields rise amid combined financial information, Brexit deal optimism

Treasury yields rise amid mixed economic data, Brexit deal optimism

Government bond yields remained stable on Wednesday as investors digested a mix of economic data as well as signs of an impending Brexit trade deal between the UK and the European Union.

The yield on the benchmark 10-year Treasury note rose 3 basis points to 0.956%, while the yield on the 30-year government bond rose 4 basis points to 1.696%. Bond yields move inversely with prices.

Unemployment claims in the United States stood at 803,000 for the week ending December 19, the Department of Labor said on Wednesday. Economists polled by Dow Jones expected the initial claims to rise to 888,000. However, personal income declined 1.1% in November, compared to an estimate of 0.3% according to data from Dow Jones.

The yield on 10-year government bonds peaked when Brexit negotiators were on the verge of a new trade deal between the UK and the European Union. A deal would avoid tariffs due to come into effect at the beginning of the year.

President Donald Trump proposed on Tuesday not to sign a lengthy coronavirus aid package. He poured cold water on the $ 900 billion Covid relief bill that Congress passed earlier this week. Calling the measure an inappropriate “disgrace”, he called on lawmakers to make a number of changes, including larger direct payments to individuals and families.

The current package includes an increase in unemployment benefits, more small business loans, an additional $ 600 in direct payment, and funding to streamline the critical distribution of Covid-19 vaccines. However, Trump was dissatisfied with the $ 600 direct payments and requested an increase to $ 2,000.

Investors were also upset this week by a new strain of coronavirus first identified in the UK. The variant is believed to be up to 70% more transmissible than previous strains.

Categories
Health

Moderna Vaccine Is Extremely Protecting and Prevents Extreme Covid, Knowledge Present

Moderna Vaccine Is Highly Protective and Prevents Severe Covid, Data Show

WASHINGTON – Newly released data confirmed on Tuesday that Moderna’s coronavirus vaccine offers high levels of protection and sets the stage for this week’s emergency approval from federal regulators and beginning its spread across the country.

The Food and Drug Administration intends to approve use of the vaccine on Friday, said people familiar with the agency’s plans. The decision would give millions of Americans access to a second coronavirus vaccine as early as Monday.

The FDA review confirms Moderna’s earlier assessment that the vaccine had an efficacy rate of 94.1 percent in a study of 30,000 people. Side effects, including fever, headache, and fatigue, were uncomfortable but not dangerous, the agency found.

The success of Moderna’s vaccine has become all the more important to fighting the pandemic as other vaccine efforts have stalled. The hopeful news comes at a time with a record number of coronavirus cases overwhelming hospitals and an ever-increasing death toll that hit a bleak milestone of 300,000 on Monday.

The data release is the first step in a public review process that includes a one-day meeting on Thursday by an independent panel of experts. You will hear from Moderna, FDA scientists, and the public before they vote on whether to recommend approval. The panel is expected to vote yes and the FDA generally follows the experts’ recommendations.

Distribution of about six million doses could then begin next week, significantly adding to the millions of doses already developed by Pfizer and BioNTech, the companies that only released the first emergency coronavirus vaccine last Friday . Healthcare workers received the first shots of the Pfizer BioNTech vaccine Monday with an efficacy rate of 95 percent.

The introduction of vaccines has been eagerly anticipated and is one of the most ambitious vaccination campaigns ever carried out in the United States.

Last summer, the federal government signed contracts with Moderna and Pfizer to dispense a total of 200 million cans in the first quarter of 2021. Since both vaccines require two doses, these contracts guaranteed enough doses for 100 million people.

Last week the government announced that it had bought an additional 100 million doses of Moderna for the second quarter, bringing the number of Americans who can be vaccinated to 150 million. That leaves the question of how and when the 180 million or so other Americans will be covered.

Both vaccines are made available to the public free of charge.

Moderna’s vaccine has become a symbol of government scientists’ successes during the pandemic. After China released the genetic sequence of the new virus in early January, scientists from Moderna and the National Institutes of Health were able to focus on designing a vaccine in just two days. Unlike Pfizer, Moderna has a close relationship with Operation Warp Speed, the federal program that seeks to get a vaccine to market quickly. Nearly $ 2.5 billion federal funding helped Moderna buy raw materials, expand its factory, and increase its workforce by 50 percent.

Moderna’s success contrasts with two other high profile projects the US had hoped would increase vaccine supply: one from pharmaceutical companies Sanofi from France and GlaxoSmithKline from the UK and one from Anglo-Swedish drug maker AstraZeneca and the Oxford University.

AstraZeneca and Oxford used two different doses in clinical trials in the UK and Brazil. The effectiveness was 62 percent at one level and 90 percent at the other. These jumbled results have made it unclear when AstraZeneca will have enough data to obtain an emergency clearance.

Meanwhile, Sanofi and GlaxoSmithKline received disappointing results with their vaccine in early clinical trials. While it produced a promising immune response in volunteers under the age of 50, it did not do so in older people. The companies are now planning a series of new studies with a different version of the vaccine. Due to the delay, they are unlikely to provide vaccines before the end of 2021.

Moderna’s vaccine worked equally well in white volunteers and in color communities. There was also no significant difference between protecting men and women or between healthy volunteers and those at risk for severe Covid-19 who developed conditions such as obesity and diabetes. For people aged 65 and over, the study found an estimated effectiveness of 86.4 percent, which is below the overall estimate of 94.1 percent. However, the apparent difference was not statistically significant.

So far, FDA reviews have shown two possible differences between vaccines, but the results may reflect a lack of data more than real differences. The Pfizer BioNTech study showed that the vaccine began protecting against the coronavirus within about 10 days of the first dose. The experiment with the vaccine from Moderna, however, did not show such a noticeable effect after the first dose.

However, in the early days of the Moderna study, there were fewer cases of Covid-19 among study participants, making it more difficult to measure the differences between the vaccinated group and the placebo group. In either case, health officials have said that for both vaccines, two doses are essential for complete protection.

Updated

Dec. 15, 2020 at 9:31 am ET

A second difference concerns the ability to prevent serious diseases. Moderna presented more evidence that its vaccine can, according to the review. In his study, 30 volunteers developed severe cases of Covid. All of them belonged to the placebo group, with no cases among the vaccinated people.

In the Pfizer BioNTech study, the results were less convincing. There were 10 severe cases in the placebo group and one in the vaccinated group. These numbers are too few to assess the vaccine’s ability to prevent serious diseases.

“The data available for these results did not allow firm conclusions,” said the FDA.

The documents released on Tuesday made it clear that side effects were particularly common after the second dose, but usually lasted only one day. Experts say people may need to take a day off after the shot.

During the Moderna trial, researchers also kept an eye out for volunteers who developed new disorders. In a multi-month study of 30,000 volunteers, it is normal for some to have conditions unrelated to the vaccine, health experts say. Comparing the rates between people receiving the vaccine and placebo, as well as general background rates, can help identify serious concerns and eliminate coincidences.

During the Moderna study, three vaccinated participants developed a form of temporary facial paralysis called Bell’s palsy, while one participant on the placebo experienced the same. Bell’s palsy, which can last weeks or longer, can be triggered by viral infections and other causes. Around 40,000 people develop the disease in the United States each year. Years of intensive research have found no evidence that any vaccine routinely recommended in the US causes Bell’s palsy.

In the review released Tuesday, the FDA said, “There is insufficient information currently available to establish a causal relationship with the vaccine.”

The Pfizer BioNTech study identified four cases in the vaccine group, including one in a person with a history of the disorder and none in the placebo group.

Dr. Peter Marks, the FDA’s lead vaccine regulator, said in an interview with JAMA Monday that the cases of Bell’s palsy in the study were most likely not caused by the vaccine and that the apparent difference between the two groups of volunteers was only one reason Random question.

“Our working hypothesis is just that this is an imbalance in the background rates, as we’ve seen in other studies,” he said.

In its analysis of the Moderna vaccine released Tuesday, the FDA said it plans to recommend prosecuting Bell palsy cases when the vaccines are rolled out.

“We’re going to ask about this just to wrap up that question,” said Dr. Marks on Monday.

The FDA’s analysis did not reveal any serious allergic reactions to the Moderna vaccine. The same was true for the Pfizer-BioNTech clinical trial, but when vaccinations began in the UK outside of that study, two people with a history of serious allergies had a severe and potentially life-threatening reaction called anaphylaxis.

UK health officials have said people with a history of anaphylaxis should avoid the Pfizer BioNTech vaccine.

In the United States, the Centers for Disease Control and Prevention has stated that people with serious allergies can be safely vaccinated, with close monitoring for 30 minutes after receiving the shot.

Moderna and Pfizer-BioNTech vaccines are similar in their ingredients, but not identical. Therefore, it is not clear whether an allergic reaction to one vaccine would occur with the other. Both are made up of genetic material called mRNA that is enclosed in a bladder made of a mixture of fats. The two companies use different fats.

Moderna has applied for approval to vaccinate people aged 18 and over, as in its study. The Pfizer BioNTech vaccine was approved for people aged 16 and over because the study included a number of younger volunteers. Both companies are conducting experiments with children aged 12 and over and plan to also study younger children.

Sharon LaFraniere contributed to the coverage.

[Like the Science Times page on Facebook. | Sign up for the Science Times newsletter.]

Categories
Health

Some States Balk After C.D.C. Asks for Private Knowledge of These Vaccinated

Some States Balk After C.D.C. Asks for Personal Data of Those Vaccinated

“This is a new activity for us because we don’t typically report this level of detail to the federal government at this frequency,” Doug Schultz, a spokesman for the Minnesota Department of Health, said in an email. He added, “We will not provide a name, zip code, race, ethnicity or address.”

Tracking vaccinations, including collecting personal information, is not a new practice, and experts say this is especially important with a vaccine that requires two doses. But in the United States, it was a purely state effort. A push two decades ago to develop a federal registry that imploded after an uproar over patient privacy and the use of the data.

“The general philosophy in this country is that states manage public health. Therefore, the concept that we keep track of identified information at the federal level is important,” said Dr. Shaun J. Grannis, professor of medical informatics at Indiana University, who advised the CDC on data collection.

“We are 50 different states with a patchwork of regulations and different perspectives on privacy and security,” added Dr. Grannis added. “And I think people will ask the question: what does the CDC do that we cannot do regionally?”

However, the state registers differ in terms of sophistication and quality. Speaking at Monday’s briefing, Colonel RJ Mikesh of the Army, the information technology director for Operation Warp Speed, said the data collection was part of an “all America approach” to vaccine distribution.

And some experts say that amid a pandemic that has already cost nearly 284,000 lives in the US, privacy must give way to the public good and that vaccinating all Americans is a monumental task that requires federal intervention.

“We’re in a pandemic,” said Dr. Carlos del Rio, an infectious disease expert at Emory University in Atlanta. “Privacy has its role, but it can’t be what drives decision-making when you’re trying to do a monumental task like vaccinating millions of Americans with one vaccine that requires two doses.”